CellWell record HH-344482
EFFICACY OF PCSK9 INHIBITORS IN ADDITION TO BACKGROUND STATIN THERAPY COMPARED WITH PLACEBO IN ACHIEVING LDL-C TARGETS IN ADULTS WITH HYPERLIPIDAEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Pranab das; Mukundam Borah
International Journal of Current Pharmaceutical Research ยท 2026
In plain language
In this meta-analysis of five randomized trials, adding PCSK9 inhibitors to background statins made adults with hyperlipidaemia about 2.6 times more likely to reach LDL cholesterol targets than placebo, despite high heterogeneity.
- Evidence
- Emerging
- Design
- Primary research (design unspecified)
Cite this record: https://thecellwell.org/studies/HH-344482
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.